2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 161

Are Ultrasound Definitions in Gout Reliable?: Preliminary Results from a Latin American Reliability Exercise
Abstract Number: 2568

ARL15 expressed By Rheumatoid Arthritis Synovial Fibroblasts Regulates IL6 and Plays a Role in Apoptosis and Hypoxia
Abstract Number: 863

Arterial Lesions in Giant Cell Arteritis
Abstract Number: 2191

Arthritis As a Potential Barrier to Physical Activity Among Adults with Depression – United States, Behavioral Risk Factor Surveillance System, 2013
Abstract Number: 74

Arthritis-Associated DNA Hypermethylation Provokes Increased Antibody Expression in Mouse Model of Rheumatoid Arthritis
Abstract Number: 1732

Articular and Axial Involvement Differences in Psoriatic Arthritis Patients Treated with Golimumab in Canadian Real-World Practice
Abstract Number: 1355

ASAH1 Gene Mutations Cause Acid Ceramidase Deficiency (Farber Disease), with Symptoms Including Arthritis and Subcutaneous Nodules. Patients Are Often Misdiagnosed with JIA, and Slowly Progressive Disease May Only be Diagnosed in Adulthood
Abstract Number: 691

ASAS Health Index for Patients with Spondyloarthritis: Translation into Spanish, Validation, Reliability and Construct Validity
Abstract Number: 3215

ASK1 Is Regulated By IL-1β and TNF and Modulates Key Rheumatoid Arthritis (RA) Fibroblast-like Synoviocyte Functions (FLS)
Abstract Number: 159

Assessing Agreement Among Measures of Inflammation Detected on Magnetic Resonance Imaging, Ultrasound and Clinical Findings in the Feet of Patients with Early Rheumatoid Arthritis
Abstract Number: 2039

Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Abstract Number: 3154

Assessing Bone Erosions in the Metatarsophalangeal Joints of Patients with Early Rheumatoid Arthritis: a Comparison Between MRI and Ultrasound
Abstract Number: 3137

Assessing System-Level Performance Measures for Early Rheumatoid Arthritis in a Large Multicenter Cross-Country Prospective 8-Year Observational Cohort Study
Abstract Number: 3140

Assessment of American College of Rheumatology Gout Quality Measures at a University Practice Plan
Abstract Number: 605

Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA®), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].